麝香保心丸联合川芎嗪治疗慢性肺源性心脏病急性加重期的效果观察

Abstract
Figure/Table
References (20)
Related Citation (2)

Download: PDF (0 KB) HTML (47 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the effect of Shexiang Baoxin Pills combined with Ligustrazine in the treatment of acute exacerbation of chronic pulmonary heart disease.MethodsFrom June 2016 to May 2017,100 patients with acute exacerbation of chronic pulmonary heart disease were selected as subjects and randomly divided into four groups(A,B,C and D,respectively)according to the random comprehensive sequentialmethod,each group of 25 cases.Group A was given routinewesternmedicine comprehensive treatment.Group B was given Shexiang Baoxin Pills orally on the basis of routine western medicine comprehensive treatment,2 tablets per time,three times per day,used for 10 days.Group C was treated with Ligustrazine 120 mg added into the 250 ml 5%glucose injection or 0.9%sodium chloride injection intravenous drip for 10 days.Group D was treated with Shexiang Baoxin Pills orally,2 tablets per time,three times per day,and combination with Ligustrazine 120mg added into the 250ml 5%glucose injection or 0.9%sodium chloride injection were injected intravenously for 10 days,on the basis of routine Western medicine.The brain natriuretic peptide(BNP),the first second forced expiratory volume ratio　(FEV1%),arterial blood oxygen partial pressure(PaO2),arterial blood carbon dioxide partial pressure　(PaCO2)and treatment total efficiency before and after treatmentwere compared with the four groups of patients.ResultsAfter treatment,the BNP levels of patients in the A,B,C group were lower than before the treatment,the differenceswere statistically significant(P＜0.05),while therewas no statistically significant difference of patients in group D before and after treatmentwith BNP levels(P＞0.05).The BNP level of group D was higher than that of group A,B and C,and the differences were statistically significant(P＜0.05).After treatment,the FEV1%and PaO2in the four groupswere higher than before treatment,and the differenceswere statistically significant(P＜0.05).After treatment,the FEV1%and PaO2in group D were higher than those in the group A,B and C,and PaCO2was lower than that in the group A,B and C,with statistically significant differences　(P＜0.05).The total effective rate of clinical treatment in group D was higher than that in group A,B and C,and the differenceswere statistically significant(P＜0.05).ConclusionShexiang Baoxin Pills combined with Ligustrazine in the treatment of acute exacerbation of chronic pulmonary heart disease has a significanteffect on improving cardiopulmonary function.

Key words： Shexiang Baoxin Pills Ligustrazine Acute exacerbation of chronic pulmonary heart disease

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WAN Le-le
	YISong-gang
	AO Su-min

Cite this article:

WAN Le-le,YISong-gang,AO Su-min. Effect observation of Shexiang Baoxin Pills combined w ith Ligustrazine in the treatment of acute exacerbation of chronic pulmonary heart disease[J]. 中国当代医药, 2018, 25(16): 153-156.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I16/153

[1]	杨生岳，冯恩志，闫自强，等.红景天和葛根素对高原地区慢性阻塞性肺疾病急性加重期合并慢性肺源性心脏病患者肺动脉高压的干预作用研究[J].中国中西医结合急救杂志，2013，14（1）：20-23.
[2]	徐培国，王孟仪.1977年全国慢性肺原性心脏病心电图诊断标准的探讨[J].泸州医学院学报，1979，11（2）：23-24.
[3]	葛均波，徐永健.内科学[M].8版.北京：人民卫生出版社，2013：110-115.
[4]	王丽环，孙强.川芎嗪注射液对肺心病肺动脉高压的影响[J].临床肺科杂志，2013，18：1429-1431.
[5]	刘会芳.川芎嗪对心血管系统的作用及机制研究进展[J].中国药房，2007，18（9）：706.
[6]	张民，赵锋.氯吡格雷联合低分子肝素钙对急性加重期慢性肺源性心脏病的临床效果[J].中外医学研究，2016，14（6）：18-20.
[7]	鲁保龙，马燕，张杰.探讨呼吸指数对慢性肺心病急性加重期呼吸衰竭患者的临床意义[J].中外医学研究，2016，14（21）：27-29.
[8]	邹斌，邹容.呋塞米联合依那普利在慢性肺源性心脏病心力衰竭治疗中的应用[J].中国当代医药，2016，23（33）：44-46.
[9]	曾省都，吴国斌.慢性肺源性心脏病患者采用安体舒通、托拉塞米治疗效果探究[J].中国当代医药，2017，24（30）：83-85.
[10]	倪挺，刘奇良.前列腺素E1联合低分子肝素钙对慢性肺源性心脏病患者肺动脉压和相关生化指标的影响[J].临床和实验医学杂志，2016，15（5）：453-456.
[11]	王受益，戴瑞鸿，金椿.麝香保心丸治疗冠心病心绞痛的临床观察[J].中国中西医结合杂志，1996，16（12）：717.
[12]	张奇志，卜培莉，于文强，等.麝香保心丸对自发性高血压大鼠心肌纤维化的干预研究[J].中西医结合心脑血管病杂志，2008，6（5）：546-548.
[13]	乔人立.重新认识慢性阻塞性肺疾病与肺源性心脏病[J].中华结核和呼吸杂志，2011，34（4）：246-247.
[14]	李宏礼，吴蓉.酚妥拉明联合川芎嗪注射液治疗慢性肺源性心脏病心力衰竭的疗效观察[J].实用心脑肺血管病杂志，2012，20（10）：1679-1680.
[15]	王天明，刘存根，刘春翠，等.酚妥拉明联合丹参川芎嗪注射液治疗慢性肺源性心脏病急性加重期疗效观察[J].现代中西医结合杂志，2011，20（13）：1609-1610.
[16]	王莉，汤燕，巨安丽.丹参川芎嗪注射液联合前列地尔注射液治疗慢性肺源性心脏病急性加重期的临床疗效分析[J].实用心脑肺血管病杂志，2015，16（9）：108-113.
[17]	姜龙军，吴建新，赵容军，等.参附注射液联合丹参川芎嗪注射液治疗慢性肺源性心脏病心力衰竭的临床观察[J].中国药房，2015，22（18）：2483-2485.
[18]	周松林，徐文波.川芎嗪注射液治疗慢性肺源性心脏病急性发作期的临床疗效[J].实用心脑肺血管病杂志，2015，14（2）：108-109.
[19]	赵雪林.盐酸川芎嗪注射液治疗慢性肺源性心脏病合并心力衰竭的临床疗效观察[J].医学临床研究，2013，30（6）：1164-1165.
[20]	杨华.川芎嗪注射液对慢性肺源性心脏病患者生命质量及氧化应激的影响[J].中国中医急症，2014，23（2）：351-352.